Exciting #COVID19 news: Interim results show monoclonal antibody therapy reduced hospitalizations from 6% (placebo group) to 1.7% (treated group) — a 72% reduction in risk. An Experimental Drug Protects Covid-19 Patients, Eli Lilly Claims https://t.co/CmM308aU3D

— Dr. Mark Slifka (@MarkSlifka) September 16, 2020

An Experimental Drug Protects Covid-19 Patients, Eli Lilly Claims. The man made monoclonal antibody lowered blood levels of the coronavirus and prevented hospitalizations. The research has not yet been vetted by independent experts https://t.co/GWsQTYhLID

— C. Michael Gibson MD (@CMichaelGibson) September 16, 2020

Therapy hope? Drug maker claims monoclonal antibody treatment shows promise in addressing early stages of COVID-19 infection! Unlike other therapies, this may halt infection before illness severity. https://t.co/bXgyKlfkHP @TIAscience @AlfonsoSDGs @JuliaFliss@caroyce @CTScience

— Michael DiSpezio (@mdispezio) September 16, 2020

Eli Lilly announced this morning that its antibody-based drug appears to have reduced the rate of hospitalization for coronavirus patients recently diagnosed with mild-to-moderate symptoms, according to mid-stage trial results. https://t.co/Agfyjv32PA

— Alicia Smith (@Alicia_Smith19) September 16, 2020

Coronavirus: Eli Lilly reports lower hospitalization rate with its antibody treatment https://t.co/5DTEb8NspF

— Manny Heer (@MannyHeer__) September 16, 2020

$SRNE Excellent News! Sorrento's Antibody drugs needed validation. Eli Lilly $LLY said Wednesday its antibody-based drug appears to have reduced the rate of hospitalization for coronavirus patients recently diagnosed with mild-to-moderate symptoms. https://t.co/UMOSEU5mUJ

— Max Davids (@maxdavids) September 16, 2020